Published in J Infect Dis on March 31, 2014
Quinolinic acid/tryptophan ratios predict neurological disease in SIV-infected macaques and remain elevated in the brain under cART. J Neurovirol (2015) 0.81
SAMHD1 transcript upregulation during SIV infection of the central nervous system does not associate with reduced viral load. Sci Rep (2016) 0.78
Disturbed Amino Acid Metabolism in HIV: Association with Neuropsychiatric Symptoms. Front Psychiatry (2015) 0.78
Independent and co-morbid HIV infection and Meth use disorders on oxidative stress markers in the cerebrospinal fluid and depressive symptoms. J Neuroimmune Pharmacol (2015) 0.77
Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression. J Acquir Immune Defic Syndr (2015) 0.76
Δ9-Tetrahydrocannabinol (Δ9-THC) Promotes Neuroimmune-Modulatory MicroRNA Profile in Striatum of Simian Immunodeficiency Virus (SIV)-Infected Macaques. J Neuroimmune Pharmacol (2015) 0.75
Distinct Patterns of Tryptophan Maintenance in Tissues during Kynurenine Pathway Activation in Simian Immunodeficiency Virus-Infected Macaques. Front Immunol (2016) 0.75
HIV, Tat and dopaminergic transmission. Neurobiol Dis (2017) 0.75
Frontline Science: CXCR7 mediates CD14(+)CD16(+) monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS. J Leukoc Biol (2017) 0.75
Phytochemical Inhibition of Multidrug Resistance Protein-1 as a Therapeutic Strategy for Hemangioendothelioma. Antioxid Redox Signal (2016) 0.75
Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J (1991) 11.86
The neuropathogenesis of AIDS. Nat Rev Immunol (2005) 6.54
The AIDS dementia complex: II. Neuropathology. Ann Neurol (1986) 5.61
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov (2003) 4.58
Reactive oxygen species and the central nervous system. J Neurochem (1992) 4.27
Metabolism and functions of glutathione in brain. Prog Neurobiol (2000) 3.74
Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci (2002) 2.39
Distribution of brain HIV load in AIDS. Brain Pathol (1998) 2.36
High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol (1999) 2.08
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99
Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol (2005) 1.98
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology (2007) 1.90
Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res (2006) 1.61
The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment. J Neurovirol (2008) 1.54
Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain Imaging Behav (2011) 1.53
Distinct monoamine oxidase A and B populations in primate brain. Science (1985) 1.50
Coordinated regulation of SIV replication and immune responses in the CNS. PLoS One (2009) 1.49
Redox status of cells influences constitutive or induced NF-kappa B translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J Immunol (1992) 1.48
MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One (2008) 1.39
Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction. J Neurovirol (2007) 1.30
Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology (2009) 1.30
Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci U S A (1989) 1.24
Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J Neurovirol (2010) 1.16
The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm (1980) 1.08
Central nervous system correlates of behavioral deficits following simian immunodeficiency virus infection. J Neurovirol (2003) 1.08
Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology (2011) 1.07
HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res Brain Res Rev (2005) 1.05
Oxidative stress and therapeutic approaches in HIV dementia. Antioxid Redox Signal (2006) 1.04
Dysregulation of mitogen-activated protein kinase signaling pathways in simian immunodeficiency virus encephalitis. Am J Pathol (2004) 1.04
Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling. Adv Biol Regul (2012) 1.02
Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol (2001) 1.00
Dopaminergic neurotoxicity of HIV-1 gp120: reactive oxygen species as signaling intermediates. Brain Res (2009) 0.99
Developments in HIV neuropathogenesis. Curr Pharm Des (2006) 0.99
Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport (1996) 0.98
Activation of human monoamine oxidase B gene expression by a protein kinase C MAPK signal transduction pathway involves c-Jun and Egr-1. J Biol Chem (2002) 0.98
Mechanisms of minocycline-induced suppression of simian immunodeficiency virus encephalitis: inhibition of apoptosis signal-regulating kinase 1. J Neurovirol (2008) 0.95
Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials (2007) 0.94
Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology (2000) 0.92
Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology (2012) 0.91
Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. J Neurochem (2005) 0.89
Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease. J Neuroimmune Pharmacol (2011) 0.88
Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression. Neurobiol Dis (2010) 0.85
Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm Gen Sect (1993) 0.84
Mitogen-activated protein kinase p38 in HIV infection and associated brain injury. J Neuroimmune Pharmacol (2011) 0.83
MicroRNA-142 reduces monoamine oxidase A expression and activity in neuronal cells by downregulating SIRT1. PLoS One (2013) 0.81
Serine 209 resides within a putative p38(MAPK) consensus motif and regulates monoamine oxidase-A activity. J Neurochem (2009) 0.81
Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology (1997) 0.80
HIV-1 reactivation after an oxidative stress mediated by different reactive oxygen species. Chem Biol Interact (1994) 0.79
Splenic Damage during SIV Infection: Role of T-Cell Depletion and Macrophage Polarization and Infection. Am J Pathol (2016) 0.79
Marked Enteropathy in an Accelerated Macaque Model of AIDS. Am J Pathol (2017) 0.75
HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via β-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. Am J Pathol (2017) 0.75
Lymphocyte-Dominant Encephalitis and Meningitis in Simian Immunodeficiency Virus-Infected Macaques Receiving Antiretroviral Therapy. Am J Pathol (2017) 0.75